<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00928811</url>
  </required_header>
  <id_info>
    <org_study_id>17718</org_study_id>
    <secondary_id>CHI 621A</secondary_id>
    <nct_id>NCT00928811</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety of Chronic Administration of Simulect to Subjects Receiving a First Kidney Transplant</brief_title>
  <acronym>Simulect</acronym>
  <official_title>One-year Exploratory Study to Evaluate the Safety of Partial Replacement of CNI With Chronic Administration of Simulect in de Novo Normal-risk Kidney Transplant Recipients Treated With MPA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Drexel University College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Drexel University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is undertaken to explore the safety of using Simulect at monthly dose intervals to&#xD;
      reduce the need of high dose/level CNI's such as Prograf.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of CNI's after kidney transplantation is associated with typical adverse effects such&#xD;
      as potential contribution to progressive impairment of renal function, hypertension, and&#xD;
      metabolic abnormalities. The study consists of a run-in phase (1 month),and treatment phase&#xD;
      (11 months) and safety assessment phase (1 month).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Investigator left University 04/2010&#xD;
  </why_stopped>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the risk of sensitization against the chimeric antibody, Simulect.</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To describe the pharmacokinetics of Simulect over the study course.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the absolute and relative number of CD25 receptors on T cells at the end of each dosing interval.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the difference in calculated and measured GFR.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the difference in biopsy proven acute rejection rates and the acute and chronic parameters (chronic allograft injury) on surveillance biopsies.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the difference in vital signs and lab abnormalities</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the difference in incidence and severity of albuminuria/proteinuria</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To collect safety data on infections and malignancies</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard of care administration with Simulect (basiliximab)being administered as per induction therapy on day of transplant and day 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simulect</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simulect (basiliximab) intravenously day of transplant and day 4.&#xD;
Chronic Simulect (basiliximab) administration monthly for one year duration.&#xD;
Concomitant decrease in Prograf administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>basiliximab</intervention_name>
    <description>Simulect 20 mg intravenously day of transplant and day 4</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Simulect</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>basiliximab</intervention_name>
    <description>Simulect (basiliximab) 20mg intravenously day of transplant and day 4 post operatively. Then Monthly administration of Simulect (basiliximab) 40 mg intravenously for one year duration.</description>
    <arm_group_label>Simulect</arm_group_label>
    <other_name>Simulect (basiliximab)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female 18-75&#xD;
&#xD;
          -  First kidney transplant from a living or deceased donor&#xD;
&#xD;
          -  Receiving CNI and MPA&#xD;
&#xD;
          -  Able to tolerate full dose MPA&#xD;
&#xD;
          -  Calculated glomerular filtration rate &gt;=30ml/min by Cockcroft-Gault equation&#xD;
&#xD;
          -  Able to tolerate renal graft biopsies&#xD;
&#xD;
          -  Provided written, informed consent&#xD;
&#xD;
          -  Females of childbearing potential must have a negative pregnancy test within 48 hours&#xD;
             prior to the first Simulect administration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to Simulect&#xD;
&#xD;
          -  Current preformed PRA&gt;10%&#xD;
&#xD;
          -  Multi organ or second kidney transplant&#xD;
&#xD;
          -  Use of any investigational immunosuppressive drug within 1 month of inclusion&#xD;
&#xD;
          -  Female patients who are pregnant, lactating or of child bearing potential and not&#xD;
             practicing two approved methods of birth control&#xD;
&#xD;
          -  Known malignancy or history of malignancy other than excised basal or squamous cell&#xD;
             carcinoma of the skin&#xD;
&#xD;
          -  HBV, HCV, or HIV positive patients&#xD;
&#xD;
          -  Current severe infection&#xD;
&#xD;
          -  Receiving an organ from an extended criteria donor per United Network for Organ&#xD;
             Sharing (UNOS) guidelines&#xD;
&#xD;
          -  Dialysis dependent one month post transplant&#xD;
&#xD;
          -  Live too far away from the transplant center for adequate follow up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mysore Anil S. Kumar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Drexel University College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Drexel University College of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>June 25, 2009</study_first_submitted>
  <study_first_submitted_qc>June 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2009</study_first_posted>
  <last_update_submitted>February 9, 2015</last_update_submitted>
  <last_update_submitted_qc>February 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Drexel University</investigator_affiliation>
    <investigator_full_name>cynthia gifford</investigator_full_name>
    <investigator_title>Research Administrator</investigator_title>
  </responsible_party>
  <keyword>Simulect</keyword>
  <keyword>de novo kidney transplant subjects</keyword>
  <keyword>calcineurin inhibitors</keyword>
  <keyword>Prograf</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Basiliximab</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 15, 2016</submitted>
    <returned>November 1, 2016</returned>
    <submitted>July 25, 2017</submitted>
    <returned>August 24, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

